You are using an old and unsupported browser. Most core functionality will not work. Please upgrade to a supported browser - Google Chrome

Home
Topics
Times are shown in your local time zone (GMT )

Atropine Update - Rethinking Myopia Management with Low-dose Atropine (T)

Description
WAVE On Demand Day1-Clark: Atropine Update

WAVE On Demand Notification - Please click here to notify us you are watching this On Demand. 
This will ensure your CPD is uploaded quickly.
Certificate Notifications will be sent at the time of CPD verification by the OWA Office.

If you are watching this for the first time and intend to claim the CPD time of 0.75hrs - expect your CPD to be uploaded within 14 days of viewing.
Non members will also be contacted within this timeframe.  For your information, completing and passing 3 out of the 5 optional MCQS will give you an additional 0.25 CPD hrs, making this WAVE On Demand worth 0.75CPD Hrs.

If you are watching to recap as you have already seen this presentation at WAVE Live, you are very welcome to watch any WAVE Live presentation but will not be eligible for any CPD.

Summary  It has been nearly 15 years since ATOM confirmed atropine 1% is effective in slowing myopia progression and 8 years since ATOM2 reported very low-dose atropine (0.01%) was effective longer term and well tolerated. Atropine 0.01% has become “standard of care” for treating myopic progression throughout south-east Asia on the basis of this trial. The recent Low-dose Atropine for Myopia Progression (LAMP) 2-year results showed 0.05% atropine was more effective than 0.01% and well tolerated in Hong Kong children.  The WA ATOM trial in Perth will add to the evidence for atropine use in children outside Asia. There is clearly no “one size fits all” solution to treating myopic progression and this talk aims to unpack the evidence and provide a practical approach to atropine prescribing for progressive myopia.

Key learning objective
Understand the latest evidence on atropine for the treatment of progressive myopia.


Assessment:  There are 5 optional MCQS with this lecture.

Resources

Summary It has been nearly 15 years since ATOM confirmed atropine 1% is effective in slowing myopia progression and 8 years since ATOM2 reported very low-dose atropine (0.01%) was effective longer term and well tolerated. Atropine 0.01% has become “standard of care” for treating myopic progression throughout south-east Asia on the basis of this trial. The recent Low-dose Atropine for Myopia Progression (LAMP) 2-year results showed 0.05% atropine was more effective than 0.01% and well tolerated in Hong Kong children. The WA ATOM trial in Perth will add to the evidence for atropine use in children outside Asia. There is clearly no “one size fits all” solution to treating myopic progression and this talk aims to unpack the evidence and provide a practical approach to atropine prescribing for progressive myopia.
Other Suggested Sessions On Demands

The GDPR does not specifically apply to Optometry Australia / Optometry WA as the latter does not have an establishment in the EU nor intentionally engage in targeted marketing to EU individuals specifically. In relation to the management of member data Optometry Australia's current Privacy Act is fully compliant with the respective GDPR data regulations.

We use cookies to ensure you get the best experience on our platform and by continuing to use this site you agree that we can save them on your device. For more information, please read our privacy policy. Privacy Policy